等待开盘 05-12 09:30:00 美东时间
-0.130
-10.00%
U.S. stock futures up, focus on quarterly earnings of Americas Gold and Silver, ARKO Petroleum, Entera Bio, Phreesia, and Progress Software.
03-30 15:29
Entrada Therapeutics secures EU authorization for ELEVATE-45-201, a Phase 1/2 study of ENTR-601-45 for Duchenne muscular dystrophy patients amenable to exon 45 skipping. The study aims to assess safety, tolerability, and efficacy, with initiation planned for Q3 2025. ENTR-601-45 is an exon-skipping therapy designed to restore dystrophin production, addressing a significant unmet need in this DMD subpopulation.
2025-05-28 11:00